Form 4: Metagenomi CEO Sells Shares to Cover Tax Obligations from RSU Vesting

Metagenomi, Inc.'s CEO, Brian C. Thomas, reported an automatic sale of 10,785 common shares at $1.75 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.

Summary

• Brian C. Thomas, Chief Executive Officer and Director of Metagenomi, Inc. (MGX), reported a transaction on June 6, 2025.
• The transaction involved the sale of 10,785 shares of Metagenomi common stock at a price of $1.75 per share.
• This sale was explicitly stated as an automatic, non-volitional transaction, executed solely for the purpose of satisfying tax withholding obligations upon the vesting of certain restricted stock units (RSUs).
• These restricted stock units were originally granted to Mr. Thomas on April 1, 2024.
• Following this reported transaction, Mr. Thomas directly beneficially owns 2,517,491 shares of Metagenomi common stock.

Sentiment

Score: 6

Explanation: The transaction is a routine, non-volitional sale for tax purposes following RSU vesting, which is a neutral to slightly positive event (as RSU vesting implies conditions were met). It does not indicate a negative outlook from management.

Positives

• The underlying event, the vesting of restricted stock units (RSUs), indicates that performance or time-based conditions for the grant were met, which is generally a positive for the executive and potentially reflects positively on company performance or tenure.

Negatives

• The sale of shares, even for tax purposes, reduces the insider's direct ownership, though this is a common and expected occurrence with RSU vesting.
• The sale price of $1.75 per share might be considered low depending on the company's recent trading range, though the document does not provide market context.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• "These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person."

Industry Context

This filing is a routine insider transaction report (Form 4) and does not provide information relevant to broader industry trends or competitive landscape analysis. Such tax-related sales upon RSU vesting are common across all industries for executives receiving equity compensation.

Comparison to Industry Standards

• This Form 4 filing details a routine, non-volitional stock sale for tax withholding purposes, which is a standard practice for executives receiving equity compensation across publicly traded companies.
• There are no specific comparable companies, projects, or results mentioned in this document to assess against industry benchmarks.

Stakeholder Impact

• Shareholders: The sale is a routine tax-related transaction and is unlikely to signal a change in management confidence. The reduction in direct insider ownership is minimal in the context of total shares beneficially owned.
• Employees: The vesting of RSUs for the CEO may signal that equity compensation plans are functioning as intended.

Key Dates

Keywords

Metagenomi, MGX, Form 4, insider transaction, stock sale, CEO, Brian C. Thomas, restricted stock units, RSU vesting, tax withholding, beneficial ownership